BR112016006246A2 - - Google Patents

Info

Publication number
BR112016006246A2
BR112016006246A2 BR112016006246A BR112016006246A BR112016006246A2 BR 112016006246 A2 BR112016006246 A2 BR 112016006246A2 BR 112016006246 A BR112016006246 A BR 112016006246A BR 112016006246 A BR112016006246 A BR 112016006246A BR 112016006246 A2 BR112016006246 A2 BR 112016006246A2
Authority
BR
Brazil
Application number
BR112016006246A
Other languages
Portuguese (pt)
Other versions
BR112016006246B1 (pt
BR112016006246B8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016006246A2 publication Critical patent/BR112016006246A2/pt
Publication of BR112016006246B1 publication Critical patent/BR112016006246B1/pt
Publication of BR112016006246B8 publication Critical patent/BR112016006246B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR112016006246A 2013-09-24 2014-09-24 Processos de produção de derivados de diazabiciclo-octano e compostos intermediários dos mesmos BR112016006246B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-197110 2013-09-24
JP2013197110 2013-09-24
PCT/JP2014/075203 WO2015046207A1 (ja) 2013-09-24 2014-09-24 ジアザビシクロオクタン誘導体の製造法とその中間体

Publications (3)

Publication Number Publication Date
BR112016006246A2 true BR112016006246A2 (enExample) 2017-08-22
BR112016006246B1 BR112016006246B1 (pt) 2021-09-08
BR112016006246B8 BR112016006246B8 (pt) 2021-10-05

Family

ID=52743343

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006246A BR112016006246B8 (pt) 2013-09-24 2014-09-24 Processos de produção de derivados de diazabiciclo-octano e compostos intermediários dos mesmos

Country Status (22)

Country Link
US (2) US10000491B2 (enExample)
EP (1) EP3050883B1 (enExample)
JP (1) JP6453222B2 (enExample)
KR (1) KR102239725B1 (enExample)
CN (2) CN105555787B (enExample)
AR (5) AR097744A1 (enExample)
AU (1) AU2014324302B2 (enExample)
BR (1) BR112016006246B8 (enExample)
CA (1) CA2924953C (enExample)
DK (1) DK3050883T3 (enExample)
ES (1) ES2793201T3 (enExample)
HK (1) HK1244487A1 (enExample)
HU (1) HUE049027T2 (enExample)
IL (1) IL244740B (enExample)
MX (2) MX372585B (enExample)
MY (2) MY176278A (enExample)
NZ (1) NZ718009A (enExample)
RU (1) RU2719480C2 (enExample)
SG (1) SG11201602256UA (enExample)
TW (1) TWI644908B (enExample)
WO (1) WO2015046207A1 (enExample)
ZA (1) ZA201602053B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
HUE051925T2 (hu) 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása
MY190283A (en) 2014-12-05 2022-04-12 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
CA2944306C (en) 2015-10-30 2023-11-14 The Toronto-Dominion Bank Validating encrypted data from a multi-layer token
US11216808B2 (en) 2015-11-04 2022-01-04 The Toronto-Dominion Bank Token-based system for excising data from databases
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
ES3011839T3 (en) 2017-09-27 2025-04-08 Meiji Seika Pharma Co Ltd Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
KR102844744B1 (ko) 2017-09-27 2025-08-11 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조방법
WO2019064071A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN111373033A (zh) 2017-11-23 2020-07-03 豪夫迈·罗氏有限公司 脯氨酸羟化酶及其相关用途、方法和产品
WO2020018462A1 (en) 2018-07-16 2020-01-23 Brown University A chromogenic beta-lactamase substrate
WO2020059891A1 (ja) * 2018-09-21 2020-03-26 株式会社エーピーアイ コーポレーション アミノ酸誘導体の製造方法
US12195755B2 (en) 2019-05-20 2025-01-14 Brown University Placental lipid bilayer for cell-free molecular interaction studies
US11751775B2 (en) 2019-08-30 2023-09-12 DePuy Synthes Products, Inc. Electrical device for monitoring, prevention, and treatment of implant infections
CN121021508A (zh) * 2025-10-29 2025-11-28 北京耀诚惠仁科技有限公司 β-内酰胺酶抑制剂中间体共晶或盐及其制备方法和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (enExample) 1970-10-21 1975-12-10
JPS538509A (en) 1976-07-13 1978-01-26 Toshiba Corp Impedance matching system for data transmission circuit
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
NZ274915A (en) * 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
EP0758651B1 (en) 1994-05-02 2002-09-11 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2815420B1 (fr) 2000-10-16 2003-05-16 Cit Alcatel Compensation de la dispersion chromatique dans un systeme de transmission a fibre optique, et fibre de compensation
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
TWI599355B (zh) * 2010-12-22 2017-09-21 明治製菓藥業股份有限公司 光學活性二氮雜二環辛烷衍生物及其製造法
BR112013032415B1 (pt) 2011-06-17 2021-07-27 Pfizer Anti-Infectives Ab Processos para preparar compostos e compostos
PT2748165T (pt) 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
HUE051925T2 (hu) * 2013-10-08 2021-04-28 Meiji Seika Pharma Co Ltd Dizabiciklooktán származék kristályai és diazabiciklooktán származék kristályainak elõállítási eljárása

Also Published As

Publication number Publication date
HK1244487A1 (zh) 2018-08-10
CA2924953A1 (en) 2015-04-02
SG11201602256UA (en) 2016-04-28
BR112016006246B1 (pt) 2021-09-08
AR131188A2 (es) 2025-02-26
US10000491B2 (en) 2018-06-19
IL244740A0 (en) 2016-04-21
US20160264573A1 (en) 2016-09-15
AR097744A1 (es) 2016-04-13
AU2014324302B2 (en) 2018-02-15
TWI644908B (zh) 2018-12-21
ZA201602053B (en) 2019-06-26
MX367578B (es) 2019-08-27
MX2016003867A (es) 2016-08-04
CA2924953C (en) 2021-12-07
RU2719480C2 (ru) 2020-04-17
HUE049027T2 (hu) 2020-08-28
RU2016115767A (ru) 2017-10-26
KR20160058851A (ko) 2016-05-25
NZ718009A (en) 2018-03-23
TW201546059A (zh) 2015-12-16
JP6453222B2 (ja) 2019-01-16
CN107501264A (zh) 2017-12-22
EP3050883A1 (en) 2016-08-03
HK1219473A1 (zh) 2017-04-07
DK3050883T3 (da) 2020-05-25
AU2014324302A1 (en) 2016-05-12
AR131189A2 (es) 2025-02-26
MY176278A (en) 2020-07-27
MY193210A (en) 2022-09-26
RU2016115767A3 (enExample) 2018-06-29
BR112016006246B8 (pt) 2021-10-05
MX372585B (es) 2020-04-17
US20170283415A1 (en) 2017-10-05
AR131186A2 (es) 2025-02-26
ES2793201T3 (es) 2020-11-13
CN105555787B (zh) 2017-08-08
JPWO2015046207A1 (ja) 2017-03-09
AR131190A2 (es) 2025-02-26
US10000492B2 (en) 2018-06-19
EP3050883B1 (en) 2020-04-22
IL244740B (en) 2018-11-29
CN105555787A (zh) 2016-05-04
KR102239725B1 (ko) 2021-04-12
WO2015046207A1 (ja) 2015-04-02
EP3050883A4 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
BR112016010716A2 (enExample)
BR112015007533A2 (enExample)
BR112014018502A2 (enExample)
BR112014019326A2 (enExample)
BR112014018516A2 (enExample)
BR112015022748A2 (enExample)
BR112014020341A2 (enExample)
BR112014017855A2 (enExample)
BR112014017765A2 (enExample)
BR112016013983A2 (enExample)
BR112014021878A2 (enExample)
RU2016115767A3 (enExample)
BR112014018468A2 (enExample)
BR112014017901A2 (enExample)
BR112014019204A2 (enExample)
BR112014018207A2 (enExample)
BR112016009323A2 (enExample)
BR112015015948A2 (enExample)
BR112016003580A2 (enExample)
BR112016008438A2 (enExample)
BR112014018578A2 (enExample)
BR112014017794A2 (enExample)
BR112015015312A2 (enExample)
BR112014024039A2 (enExample)
BR112014018353A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2014, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2644 DE 08/09/2021 QUANTO AO TITULAR (ITEM 73) E AO TITULO (TEM 54).